Results 161 to 170 of about 1,016,909 (195)

Substance Use Disorder and Cognitive Impairment. [PDF]

Life (Basel)
Li W, Chamoun I, Ghaiye S, Ha V, Billings R.   +4 more
europepmc   +1 more source

Opioid Use Disorder Treatment Gaps and Emerging Therapeutics to Address Them. [PDF]

CNS Drugs
Banks ML.
europepmc   +1 more source

Inpatient utilization among Medicaid members with substance use disorder in Oregon. [PDF]

Subst Abuse Treat Prev Policy
Fish DJ, Holtorf M, Lacijan KA, Gronowski B, Bouldin G, Mendenhall A, Cohen-Cline H, Doren T, Livingston CJ.   +8 more
europepmc   +1 more source

Methamphetamine Use and Psychiatric Morbidity in Sri Lanka: Sociodemographic Insights from a Tertiary Care Clinic. [PDF]

Indian J Psychol Med
Galhenage J, Isuru A, Dayabandara M, Hanwella R.   +3 more
europepmc   +1 more source

Redundancy in the DSM-5 substance use disorder criterion set: Evidence from a national U.S. survey. [PDF]

Psychol Assess
Watts AL, Sexton JF, Boness CL, Christensen AP.   +3 more
europepmc   +1 more source

Co-treating opioid and alcohol use disorders in the United States, 1960-2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era. [PDF]

Drug Alcohol Depend Rep
Qeadan F, Barbeau WA.
europepmc   +1 more source

The Prevalence of Substance Use Among Students and Associated Factors: A Systematic Review With Narrative Synthesis. [PDF]

Health Sci Rep
Bazleh N.
europepmc   +1 more source

The evolving epidemiology of opioid use disorder: polysubstance use, drug supply transformation, and policy implications. [PDF]

Front Public Health
Mandapati NK, Tovar DC, Bindlish R, Hernandez YL, Alves MJ, Baum MK, Aggarwal S.   +6 more
europepmc   +1 more source

What can case-control comparisons of neural drug cue reactivity tell us about addiction? A neuroimaging meta-analysis. [PDF]

Transl Psychiatry
Fascher M, Krasowski K, Muehlhan M.
europepmc   +1 more source